Severe lichenoid eruption due to concomitant medications following nivolumab administration

Immune checkpoint inhibitors, including nivolumab, an anti-programmed death-1 (PD-1) antibody, are now used against various malignancies. While they show remarkable efficacy in a certain number of patients, also associated with variety immune-related adverse events. One such event is drug eruptions, which may present unusual clinical findings.This article protected by copyright. All rights reserved.